Table 1 Basic characteristics of the included studies
Name | Type of literature | Journal | Year Published | Trial sequence | Design | Sample | Pre-infusion conditioning | Dose | Target | Costimulatory domain | AEs criteria |
|---|---|---|---|---|---|---|---|---|---|---|---|
Ying Zhita; a | Journal | Molecular Therapy-Oncolytics | 2019 | NCT03528421 | phase 1/2 | 3 | CF | 5*10^5/kg | CD19 | CD28 | CTCAE v5.0 |
Ying Zhita;a | Journal | Molecular Therapy-Oncolytics | 2019 | NCT03528421 | phase 1/2 | 3 | CF | 5*10^5/kg | CD19 | 41BB | Not found |
Yan, Zi-Xun | Journal | Clinical Cancer Research | 2019 | NCT03355859 | phase 1 | 10 | CF | (2.5 or 5 or 10) *10^7 | CD19 | 41BB | CTCTAE v4.03 |
Sang, W | Journal | Cancer Med | 2020 | NCT03207178 | phase 2 | 21 | CF/ifosfamide | CD19: 1.0 (0.2–4.0) *10^6/kg CD20:1.0*(0.1–4.0) *10^6/kg | CD19 + CD22 | CD28 + 41BB | CTCTAE v4.03 |
Tong, C | Journal | Blood | 2020 | NCT03097770 | phase 1/2a | 28 | CF-based | 0.5*10^6–6*10^6/kg | CD19 + CD20 | 41BB | CTCAE v4.0 |
Xu, J | Journal | PNAS | 2019 | NCT03090659 | phase 1 | 17 | CF/Cy-based | 0.7(0.21–1.52) *10^6/kg | LCAR-B38M | 41BB | CTCTAE v4.03 |
Zhao, W. H | Journal | J Hematol Oncol | 2018 | NCT03090659 | phase1 | 57 | Cy | 0.5(0.07–2.1)*10^6/kg | LCAR-B38M | 41BB | CTCTAE v4.03 |
Shah, N. N | Journal | Nature Medicine | 2020 | NCT03019055 | phase 1 | 22 | CF | (2.5 or 7.5 or 25) * 10^5/kg | CD19 + CD20 | 41BB | CTCAE v5.0 |
Wang, Y | Journal | Int J Lab Hematol | 2020 | NCT02782351 | phase 1/2 | 21 | CF | 1*10^6/kg | CD19 | 41BB | CTCTAE v4.03 |
Fried, S. | Journal | Bone Marrow Transplant | 2019 | NCT02772198 | phase1b/2 | 35 | CF | CD19 | CD28 | Not found | |
An, F | Journal | Nature Communications | 2020 | NCT02735291 | phase 2 | 47 | CF/VDCP/ Cy | (1–5)*10^6/kg; ≤2*10^9 | CD19 | 41BB | CTCTAE v4.03 |
Ramos, C. A | Journal | Journal of Clinical Oncology | 2020 | NCT02690545 NCT02917083 | phase 1/2 | 42 | CF/Benda/Benda-Flu | 2*10^7cells/m2; 1*10^8cells/m2; 2*10^8 cells/m2 | CD30 | CD28 | CTCAE v4.0 |
Raje, N | Journal | N Engl J Med | 2019 | NCT02658929 | phase 1 | 33 | CF | 50、150、450、800*10^6 | BCMA | 41BB | CTCTAE v4.03 |
Abramson, J. S | Journal | lancet | 2020 | NCT02631044 | phase 1 | 269 | CF | (50 or 10 or 150) *10^6 | CD19 | 41BB | CTCTAE v4.03 |
Wang, M | Journal | N Engl J Med | 2020 | NCT02601313 | phase 2 | 68 | CF | 2*10^6/kg | CD19 | 41BB | CTCTAE v4.03 |
Cohen, A. D | Journal | J Clin Invest | 2019 | NCT02546167 | phase 1 | 25 | Cy | (1–5)*10^8 | BCMA | 41BB | CTCAE v4.0 |
Goto, H | Journal | Int J Clin Oncol | 2020 | NCT02445248 | phase 2 | 9 | CF or Benda | 2*(1–4.9)*10^8 | CD19 | 41BB | CTCAE v4.03 |
Schuster, S. J | Journal | N EngL J Med | 2018 | NCT02445248 | phase 2a | 111 | CF/Benda | 3(0.1–6)*10^8 cells | CD19 | 41BB | CTCTAE v4.03 |
Ghorashian, S | Journal | Nat Med | 2019 | NCT02443831 | phase1 | 14 | CF/Cy | 10^6/kg or 0.73–0.78*10^6/kg | CD19 | 41BB | CTCAE v4.03 |
Maude, S. L | Journal | N Engl J Med | 2018 | NCT02435849 | phase 1/2a | 75 | CF mainly | 2.9(SD1.2)*10^7/kg | CD19 | 41BB | CTCAE v4.03 |
Strati, Paolo | Journal | Haematologica | 2020 | NCT02348216 NCT03153462 | ZUMA-1 + ZUMA-9 | 31 | CF | 2*10^6/kg | CD19 | CD28 | CTCTAE v4.03 |
Locke, F. L | Journal | Lancet Oncol | 2019 | NCT02348216 | phase 1/2 | 108 | CF | 2*10^6/kg | CD19 | CD28 | CTCTAE v4.03 |
Fry, T. J | Journal | Nature medicine | 2017 | NCT02315612 | phase 1 | 21 | (3 or 10 or 30)*10^5/kg | CD22 | 41BB | Not found | |
Ali, S. A | Journal | Blood | 2016 | NCT02215967 | phase 1 | 12 | CF | (0.3 or 1 or 3 or 9)*10^6/kg | BCMA | CD28 | CTCAE v4.02 |
Enblad, Gunilla | Journal | Clin Cancer Res | 2018 | NCT02132624 | phase 1/2a | 15 | CF | (2–20)*10^7 cells/m2 | CD19 | CD28 + 41BB | Not found |
Schuster, S. J | Journal | N Engl J Med | 2017 | NCT02030834 | case-series | 28 | Cy/EPOCH/Benda/Radio+Cy/etoposide+Cy/CBP + GEM | 5.79(3.08–8.87)*10^6 /Kg | CD19 | 41BB | Not found |
Gardner, R. A | Journal | Blood | 2017 | NCT02028455 | phase 1/2 | 43 | CF/Cy | (1 or 5 or 10)*10^6/kg | CD19 | 41BB | CTCAE v4 |
Curran, K. J | Journal | Blood | 2019 | NCT01860937 | phase 1 | 25 | CF/Cy | (1 or 3)*10^6/kg | CD19 | CD28 | CTCTAE v4.03 |
Ramos, Carlos A | Journal | Molecular Therapy | 2018 | NCT01853631 | phase 1 | 16 | CF | (1 or 5 or 20)*10^6 cells/m2 | CD19 | CD28 + 41BB(2nd + 3st generation) | CTCTAE v4 |
Zhang, W. Y | Journal | Signal Transduct Target Ther | 2016 | NCT01735604 | phase 2a | 11 | Cy-based | (0.41–1.46)*10^7/ kg | CD20 | 41BB | CTCAE v3.0 |
Lee, D. Wb | Journal | Lancet | 2014 | NCT01593696 | phase 1 | 19 | CF | (1 or 3)*10^6/kg | CD19 | CD28 | CTCAE v4.02 |
Geyer, M. B. | Journal | Mol Ther | 2018 | NCT01416974 | phase1 | 8 | Cy | (3 or 10 or 30)*10^7 | CD19 | CD28 | CTCAE v4 |
Geyer, M. B | Journal | JCI Insight | 2019 | NCT00466531 | phase1 | 20 | Cy,or CF or Benda | (0.4–3.0)*10^7/kg | CD19 | CD28 | CTCAE v3.0 |
Sesques, Pc | Journal | American Journal of Hematology | 2020 | commercial CAR T cells | retrospectively | 33 | CF;/Benda | Not found | CD19 | 41BB | CTCAE v5.0 |
Sesques, Pc | Journal | American Journal of Hematology | 2020 | commercial CAR T cells | retrospectively | 28 | CF | Not found | CD19 | CD28 | CTCAE v5.0 |
Wang, Nd | Journal | Blood | 2019 | ChiCTR-OPN-16008526 | a pilot study | 51 | CF | CD19:2.6 ± 1.5*10^6/kg; CD22:2.7 ± 1.2*10^6/kg; | CD19 + CD22 | CD28 + 41BB | CTCTAE v4.03 |
Wang, Nd | Journal | Blood | 2019 | ChiCTR-OPN-16008526 | a pilot study | 38 | CF | CAR19–5.1 ± 2.1*10^6/kg; CAR22–5.3 ± 2.4*10^6/kg | CD19 + CD22 | CD28 + 41BB | CTCTAE v4.03 |
Zhou, X | Journal | Frontiers in Immunology | 2020 | ChiCTR-OOC-16007779) | phase 1 | 21 | CF | 8.9(0.3–48)* 10^5/kg | CD19 | forth generation | CTCTAE v4.03 |
Wang, Jia | Journal | British Journal of Haematology | 2020 | ChiCTR-ONN-16009862+ ChiCTR1800019622 | a pilot study | 23 | CF | 1*10^6/Kg | CD19 | 41BB | CTCAE v4.03 |
Zhiling Yan | Journal | Lancet Haematol | 2019 | ChiCTROIC-17,011,272 | phase 2 | 21 | CF | 1*10^6/kg | CD19 + BCMA | 41BB | CTCAE v4.0 |
Bao, F. | Journal | Zhonghua xueyexue zazhi | 2018 | case-series | 10 | CF | 4.27(0.30–6.93)*10^6/kg | CD19 | 41BB | CTCAE | |
Jain, T | Journal | Blood Advances | 2020 | NCT01044069; NCT03070327; commercial CAR T cells | clinical trials; retrospectively | 83 | CF/Cy/Bendam | Not found | CD19、BCMA | CD28、41BB | CTCAE v5.0 |
Popat, R | Abstract | Blood | 2019 | NCT03287804 | phase 1 | 11 | CF | (15 or 75 or 225 or 600 or 900)*10^6 | BCMA+TACI | CD28 + OX40 | Not found |
Usmani, S. Z | Abstract | HemaSphere | 2020 | NCT03548207 | phase 1b | 29 | CF | 0.73(0.5–0.9)*10^6/kg | BCMA | 41BB | CTCAE v5.0 |
Mailankody, S | Abstract | HemaSphere | 2020 | NCT034330011 | phase1/2 | 51 | CF | (300 or 450 or 600)*10^6 | BCMA | 41BB | Not found |
Hu, Jianda | Abstract | Blood | 2018 | NCT03391726 | phase 2/3 | 8 | CF | (0.7–6) *10^6/kg. | CD19 | 41BB | Not found |
Amrolia, Persis J. | Abstract | Blood | 2018 | NCT03287817 | phase 1; AUTO3 | 8 | CF | (1 or 3 or 5)*10^6/kg | CD19 + CD22 | OX40(CD19); 41BB(CD22) | Not found |
Ardeshna, Kirit | Abstract | Blood | 2019 | NCT03287817 | phase1/2; AUTO3 | 11 | CF | (50 or 150) *10^6 | CD19 + CD22 | OX40(CD19); 41BB(CD22) | Not found |
Yan, Lingzhi | Abstract | Blood | 2019 | NCT03196414 | phase 1/2 | 28 | CF | CD19 1.0*10^7/kg; BCMA(2–6.8) × 10^7/kg | CD19 + BCMA | 41BB | Not found |
Wierda, William G | Abstract | Blood | 2018 | NCT02614066 | phase 1 | 35 | CF | (0.5 or 1 or 2)*10^6/kg | CD19 | 41BB | Not found |
Topp, M. S. | Abstract | Hematological Oncology | 2019 | NCT02348216 | ZUMA-1 updated | 21 | CF | 2*10^6/kg | CD19 | CD28 | Not found |
Jiang, Songfu | Abstract | Blood | 2018 | 16 | CF | (0.5 or 1.8 or 1.5)*10^8 | BCMA | 41BB | Not found | ||
Dourthe, M. E | Abstract | Blood | 2019 | sponsored-clinical trial | 41 | CF | (2–5)*10^6/kg (weight ≤ 50 kg); (1–2.5)*10^8 /kg (weight > 50 kg) | CD19 | 41BB | Not found | |
Jacobson, Caron | Abstract | Blood | 2020 | NCT03105336 | phase 2 | 146 | CF | 2*10^6/kg | CD19 | CD28 | CTCAE v4.03 |
WayneAS | Abstract | HemaSphere | 2019 | NCT02625480 | phase1 | 24 | CF | 1 or 2*10^6/kg | CD19 | 41BB | Not found |